Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months

NCT05551858 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT05551858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05551858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months
Lead sponsor
Georgetown University
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 17, 2022
Completion date
December 31, 2031
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain, pancreas fibrosis, safety issues